z-logo
Premium
The possible role of CD 8+/Vα7.2+/ CD 161++ T ( MAIT ) and CD 8+/Vα7.2+/ CD 161 lo T ( MAIT ‐like) cells in the pathogenesis of early‐onset pre‐eclampsia
Author(s) -
Meggyes Matyas,
Szanto Julia,
Lajko Adrienn,
Farkas Balint,
Varnagy Akos,
Tamas Peter,
Hantosi Eszter,
Miko Eva,
Szereday Laszlo
Publication year - 2018
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12805
Subject(s) - perforin , peripheral blood mononuclear cell , immunology , population , immune system , chemistry , microbiology and biotechnology , biology , medicine , cd8 , biochemistry , environmental health , in vitro
Problem The objective of this study was to compare the expressions of different immune‐checkpoint molecules by MAIT and MAIT ‐like cells in healthy pregnancy and in early‐onset pre‐eclampsia. Method of study Peripheral blood mononuclear cells ( PBMC ) were stained with monoclonal antibodies to characterize MAIT and MAIT ‐like cells. Flow cytometric analyses were used to measure PD ‐1, TIM ‐3, activation markers, and intracellular perforin expression. Results We identified CD 3+/ CD 8+/Vα7.2+/ CD 161++ MAIT cells and a minor cell population characterized by CD 3+/ CD 8+/Vα7.2+/ CD 161 lo surface markers. In measuring the expression of PD ‐1 receptor, we found a significantly lower expression by MAIT cells in women with early‐onset pre‐eclampsia. CD 69 expression by MAIT cells was significantly elevated in early‐onset pre‐eclamptic patients. Intracellular perforin content by MAIT and PD ‐1+ MAIT cells was significantly increased in pre‐eclamptic patients compared with healthy individuals. Conclusion Altered frequency and reduced PD ‐1 expression combined together with the elevated perforin content of MAIT cells insinuate their potential roles in the pathogenesis of early‐onset pre‐eclampsia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here